| 產(chǎn)品編號(hào) | bs-1456R |
| 英文名稱(chēng) | Adenosine Receptor A2a Rabbit pAb |
| 中文名稱(chēng) | 腺苷A2A受體抗體 |
| 別 名 | Adenosine Receptor A2a; Adenosine A2A-R; A2AR; A2A adenosine receptor; A2AAR; A2aR; ADENO; Adenosine A2 receptor; Adenosine A2a receptor; Adenosine receptor subtype A2a; Adenosine Receptor A2a; ADORA 2; ADORA2; Adora2a; hA2aR; RDC 8; RDC8; AA2AR_HUMAN. |
 |
Specific References (3) | bs-1456R has been referenced in 3 publications.
[IF=5.195] Junnan Cai. et al. Shufeng Jiedu capsule inhibits inflammation and apoptosis by activating A2AAR and inhibiting NF-κB to alleviate LPS-induced ALI. J ETHNOPHARMACOL. 2022 Nov;298:115661 IF, WB ; Mouse.
[IF=4.366] Aleix Martí Naviaet al. Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists. Cells
. 2020 Jul 21;9(7):1739. IF ; rat.
[IF=2.34] Cao, Zhi-Ping, et al. "Effects of cordycepin on spontaneous alternation behavior and adenosine receptors expression in hippocampus." Physiology & Behavior (2017). IHC-P ; Mouse.
|
| 研究領(lǐng)域 | 心血管 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse,Rat (predicted: Rabbit,Pig,Cow,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 45 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human A2AR: 165-300/412 <Cytoplasmic> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes a member of the guanine nucleotide-binding protein (G protein)-coupled receptor (GPCR) superfamily, which is subdivided into classes and subtypes. The receptors are seven-pass transmembrane proteins that respond to extracellular cues and activate intracellular signal transduction pathways. This protein, an adenosine receptor of A2A subtype, uses adenosine as the preferred endogenous agonist and preferentially interacts with the G(s) and G(olf) family of G proteins to increase intracellular cAMP levels. It plays an important role in many biological functions, such as cardiac rhythm and circulation, cerebral and renal blood flow, immune function, pain regulation, and sleep. It has been implicated in pathophysiological conditions such as inflammatory diseases and neurodegenerative disorders. Alternative splicing results in multiple transcript variants. A read-through transcript composed of the upstream SPECC1L (sperm antigen with calponin homology and coiled-coil domains 1-like) and ADORA2A (adenosine A2a receptor) gene sequence has been identified, but it is thought to be non-coding. [provided by RefSeq, Jun 2013] Function: Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Subunit: Interacts (via cytoplasmic C-terminal domain) with USP4; the interaction is direct. May interact with DRD4. Subcellular Location: Cell membrane; Multi-pass membrane protein. Similarity: Belongs to the G-protein coupled receptor 1 family. SWISS: P29274 Gene ID: 135 Database links: Entrez Gene: 135 Human Entrez Gene: 11540 Mouse Omim: 102776 Human SwissProt: P29274 Human SwissProt: Q60613 Mouse Unigene: 197029 Human Unigene: 333734 Mouse Unigene: 11180 Rat 腺苷A2A受體參與神經(jīng)遞質(zhì)運(yùn)輸、吞噬、細(xì)胞凋亡、炎癥應(yīng)答、細(xì)胞防御應(yīng)答、信號(hào)轉(zhuǎn)導(dǎo)。 腺苷是腺嘌呤核苷酸代謝的中間產(chǎn)物。是一種保護(hù)正常組織免于炎癥損傷的關(guān)鍵的、多余的負(fù)調(diào)節(jié)免疫細(xì)胞。由cAMP 生物合成。 |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with Adenosine Receptor A2a polyclonal antibody, unconjugated (bs-1456R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|
